Abstracts Archive - Page 2002 of 2607 - ACR Meeting Abstracts

Abstract Number: 1969 • 2015 ACR/ARHP Annual Meeting
Can We Predict the Relapse of Giant Cell Arteritis?
Alojzija Hocevar, Rok Ješe, Ziga Rotar, Sonja Praprotnik, Matija Tomšič and Saša Čučnik, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Relapses during glucocorticoid (GC) tapering are frequent in giant cell arteritis (GCA). Anemia at the time of GCA diagnosis was a predictor of flare…
Abstract Number: 1970 • 2015 ACR/ARHP Annual Meeting
Incidence and Predictors of Thoracic Aortic Damage in Biopsy-Proven Giant Cell Arteritis: A Single-Institution Cohort Study
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with giant cell arteritis (GCA) are at an increased risk for aortic structural damage; however, the timing and predisposing characteristics for development of…
Abstract Number: 1971 • 2015 ACR/ARHP Annual Meeting
Healthcare Utilization and Direct Medical Costs of Giant Cell Arteritis
Matthew J. Koster¹, Sara J. Achenbach², Cynthia S. Crowson², Eric L. Matteson¹, Hilal Maradit Kremers² and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Title: Healthcare Utilization and Direct Medical Costs of Giant Cell Arteritis Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in patients aged…
Abstract Number: 1972 • 2015 ACR/ARHP Annual Meeting
Cardiovascular and Cerebrovascular Disease and Social Deprivation in Patients with Giant Cell Arteritis
Joanna Robson¹, Amit Kiran², Andrew Hutchings³, Joseph Maskell⁴, Nigel K Arden⁵, Willie Hamilton⁶, Bhaskar Dasgupta^7,8 and Raashid Luqmani⁹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ³Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁴Faculty of Medicine, University of Southampton, Southampton, United Kingdom, ⁵Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁶Primary Care, University of Exeter, Exeter, United Kingdom, ⁷Southend University Hospital, Southend, United Kingdom, ⁸Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in the UK, with an incidence of 2.2 cases per 10,000 person-years. Cerebrovascular…
Abstract Number: 1973 • 2015 ACR/ARHP Annual Meeting
Giant Cell Arteritis and Risk of Cerebrovascular Accident: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Narat Srivali² and Wonngarm Kittanamongkolchai³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ³Nephrology and hypertension, Mayo Clinic, Rochester, MN
Giant Cell Arteritis and Risk of Cerebrovascular Accident: A Systematic Review and Meta-analysisBackground/Purpose: Several chronic inflammatory disorders, such as systemic lupus erythematosus and psoriatic arthritis,…
Abstract Number: 1974 • 2015 ACR/ARHP Annual Meeting
Do Patients with Giant Cell Arteritis Meet the 2011 United Kingdom Department of Health Guidance on Physical Activity?
Joanna Robson¹, Karolina Lada², Anne Miller³, Wilby Williamson¹, Julia Newton² and Raashid Luqmani⁴, ¹Rheumatology, University of Oxford, Oxford, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Nuffield Orthopaedic Center, Oxford., Oxford, United Kingdom, ⁴Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Physical inactivity is the fourth leading risk factor for global mortality accounting for 6% of deaths. Patients with giant cell arteritis (GCA) are at…
Abstract Number: 1975 • 2015 ACR/ARHP Annual Meeting
Risk of Mortality of Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Catherine Hill¹, Rachel Black², Johannes Nossent³, Carlee Ruediger⁴, Jem Ninan⁵ and Susan Lester⁶, ¹Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia, ²Medicine, University of Adelaide, Adelaide, Australia, ³Medicine, University of Western Australia, WA, Australia, ⁴Rheumatology, The Queen Elizabeth Hospital, Woodville, Australia, ⁵Rheumatology, Modbury Hospital, Modbury, Australia, ⁶Rheumatology, Basil Hetzel Institute, QEH, Woodville South, Australia
Background/Purpose: Previous studies of mortality associated with GCA have shown conflicting results.We conducted a systematic review and meta-analysis of observational studies to compare the mortality…
Abstract Number: 1976 • 2015 ACR/ARHP Annual Meeting
Corticosteroid Therapy in Giant Cell Arteritis, Predictors for Long-Term Remission
Luigi Boiardi¹, Giovanna Restuccia², Pierluigi Macchioni¹, Francesco Muratore¹, Alberto Cavazza³, Luca Cimino⁴, Raffaella Aldigeri⁵, Mariagazia Catanoso⁶, Nicolò Pipitone⁶ and Carlo Salvarani⁷, ¹Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²Rheumatology Service, Arcispedale S Maria Nuova-IRCCS, 42100, Italy, ³Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁴Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁵Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy, ⁶Rheumatology Service, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁷Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy
Background/Purpose: The aim of our study was to determine the frequency and the predictors of long-lasting remission in a cohort of consecutive patients with biopsy-proven…
Abstract Number: 1977 • 2015 ACR/ARHP Annual Meeting
Long-Term Survival of Methotrexate in Giant Cell Arteritis Patients in Clinical Practice
Dalifer Freites Núñez¹, Zulema Rosales^1,2, Lucía Arietti¹, Leticia Leon², Inmaculada Morado¹, Benjamín Fernández-Gutiérrez³, Luis Rodriguez-Rodriguez², Juan A Jover¹ and Lydia Abasolo², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: It has is been demonstrated the safety and efficacy of Methotrexate (MTX) in the treatment of Giant Cell Arteritis (GCA) in clinical trials, but…
Abstract Number: 1978 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Large Vessel Vasculitis with Aorta Involvement. Study on 10 Patients Evaluated By Positron Emission Tomoghraphy
Carlotta Nannini¹, Stelvio Sestini², Laura Niccoli³, Emanuele Cassarà⁴, Olga Kaloudi⁵ and Fabrizio Cantini⁶, ¹Rheumatology, Prato Hospital, Prato, Italy, ²Radiology Department, Prato, Italy, ³Prato Hospital, Prato, Italy, ⁴Rheumatology, Hospital of Prato, Prato, Italy, ⁵PRato, Prato Hospital, Prato, Italy, ⁶Prato, Prato, Italy
Background/Purpose: Large vessel vasculitis (LVV) with aorta involvement are often refractory to common immunosuppressive therapy. Due to the pathogenic role of IL-6 in, we prospectively…
Abstract Number: 1979 • 2015 ACR/ARHP Annual Meeting
Baseline Data on Patients Enrolled in a Randomized, Double-Blind Trial of Tocilizumab in Giant Cell Arteritis
Katie Tuckwell¹, Neil Collinson¹, Micki Klearman², Sophie Dimonaco¹, John H. Stone³ and on behalf of the GiACTA Investigators, ¹Roche Products Ltd., Welwyn Garden City, United Kingdom, ²Genentech, South San Francisco, CA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: GiACTA, a randomized, double-blind, placebo-controlled trial of the interleukin-6 receptor alpha inhibitor tocilizumab (TCZ) in patients (pts) with giant cell arteritis (GCA), is the…
Abstract Number: 1980 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France
Alexis Regent¹, Serge Redeker², Alban Deroux³, Pierre Kieffer⁴, Kim Heang Ly⁵, Maxime Dougados⁶, Claire Larroche⁷, Loïc Guillevin¹, Laurence Bouillet⁸, Olivier Espitia⁹, Nathalie Costedoat-Chalumeau¹⁰, Martin Soubrier¹¹, Benoit Brihaye¹², François Lifermann¹³, Guillaume Lefèvre¹⁴, Xavier Puéchal¹, Luc Mouthon¹, Eric Toussirot¹⁵ and GFEV and CRI, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²43 rue de l'isle, Ch Abbeville, Abbeville, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Hopital Emile Muller, Mulhouse Cedex 1, France, ⁵CHU de Limoges, Service de médecine interne, Limoges, France, ⁶Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, ⁷Internal Medicine, Paris, France, ⁸CHU, Grenoble, France, ⁹Internal Medicine, Nantes University Hospital, Nantes, France, ¹⁰Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ¹¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ¹²Service de médecine interne et médecine polyvalente, Saint Quentin, France, ¹³CH Dax, Dax, France, ¹⁴Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁵Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose: To report the French experience on the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA) and outcome after treatment…
Abstract Number: 1981 • 2015 ACR/ARHP Annual Meeting
Increased Extracellular Water Measured By Bioimpedance Analysis in Polymyalgia Rheumatica Patients – Sign of Volume Overload
Florian Günther^1,2, Boris P. Ehrenstein², Martin Fleck¹ and Rainer Straub¹, ¹Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ²Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany
Background/Purpose: Water retention is a typical feature of acute inflammatory episodes, chiefly implemented by the sympathetic nervous system (SNS) and the hypothalamic-pituitary-adrenal (HPA) axis. This…
Abstract Number: 1982 • 2015 ACR/ARHP Annual Meeting
Sonographic Scoring of the Synovial Components in the Shoulder Revealed That Shoulder Synovitis in PMR Patients Is Milder Than That in Elderly-Onset RA Patients with PMR-like Onset
Takeshi Suzuki, Division of Allergy and Rheumatology, Japanese Red Cross Medical Center, Tokyo, Japan; Division of Rheumatology, Mitsui Memorial Hosipital, Tokyo, Japan
Background/Purpose: Through the clinical experience, we noted that there seems to be differences not in the kind or the frequency but in the severity of…
Abstract Number: 1983 • 2015 ACR/ARHP Annual Meeting
Interspinous Bursitis Evaluation By Ultrasound Is Very Useful for Diagnosis of Polymyalgia Rheumatica
Kensuke Kume¹, Kanzo Amano², Susumu Yamada¹, Toshikatsu Kanazawa³, Hiroshi Komori¹, Kazuhiko Hatta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology., hiroshima clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴Rheumatology, Hatta Clinic, Kure, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory disease of the elderly, and 2012 provisional classification criteria were suggested, however it is provisional and not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].